Nedal Adi, MD
Family Medicine · Webster, TXNPI 1093102477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,298 and has fallen 69.1% since, to $401 in 2025.
Across 321 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$798
- Amgen$788
- Novo Nordisk$594
- GSK$408
- Abbott$350
- AstraZeneca$284
- plus $3K from 31 others
Across 19 payments — averaging $3480.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$60K
- Ionis Pharmaceuticals, Inc.$5K
- Boehringer Ingelheim Pharma GmbH & Co.kg$1K
What the payments were for
- Food & beverage$5,79399%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $798 |
| Amgen(2 entities) | 46 | $788 |
| Novo Nordisk | 30 | $594 |
| GSK | 17 | $408 |
| Abbott | 10 | $350 |
| AstraZeneca | 19 | $284 |
| Novartis | 19 | $278 |
| Amarin Pharma, Inc. | 19 | $262 |
| Lilly USA, LLC | 16 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $240 |
| Pfizer | 8 | $217 |
| Esperion Therapeutics, Inc. | 12 | $191 |
| Merck | 11 | $158 |
| Johnson & Johnson | 6 | $149 |
| Astellas Pharma US Inc | 5 | $96 |
| Boehringer Ingelheim | 4 | $92 |
| Bayer | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 5 | $62 |
| Phathom Pharmaceuticals, Inc. | 2 | $56 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Shield Therapeutics Inc | 2 | $43 |
| Acerus Pharmaceuticals Corporation | 1 | $38 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Exact Sciences | 2 | $30 |
| Neuronetics, Inc. | 1 | $27 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Evoke Pharma, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Photonicare Inc | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$155
- TRELEGY ELLIPTA$103
How this compares
$5,847 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $124,166 |
| EliquisApixaban | 144 | $90,532 |
| JanuviaSitagliptin Phosphate | 48 | $55,526 |
| FarxigaDapagliflozin Propanediol | 76 | $53,154 |
| LinzessLinaclotide | 51 | $44,329 |
| JardianceEmpagliflozin | 46 | $38,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $26,053 |
| TrulicityDulaglutide | 23 | $25,839 |
| TradjentaLinagliptin | 49 | $20,380 |
| MyrbetriqMirabegron | 35 | $19,341 |
| Bydureon BciseExenatide Microspheres | 18 | $16,653 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,333 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $11,163 |
| Sevelamer Carbonate | 20 | $9,902 |
| Atorvastatin Calcium | 612 | $6,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $594 | $126,911105 claims |
| PfizerEliquis | $217 | $90,532144 claims |
| MerckJanuvia, Janumet Xr | $158 | $66,68959 claims |
| Boehringer IngelheimJardiance, Tradjenta | $92 | $59,09795 claims |
| AstraZenecaFarxiga | $284 | $53,15476 claims |
| AbbVieLinzess, Synthroid | $798 | $46,34569 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $408 | $43,70681 claims |
| Lilly USA, LLCTrulicity | $260 | $25,83923 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $19,34135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Webster
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.